Literature DB >> 10790090

Serologic diagnosis of Lyme borreliosis by using enzyme-linked immunosorbent assays with recombinant antigens.

L A Magnarelli1, J W Ijdo, S J Padula, R A Flavell, E Fikrig.   

Abstract

Class-specific enzyme-linked immunosorbent assays (ELISAs) with purified recombinant antigens of Borrelia burgdorferi sensu stricto and Western blot analyses with whole cells of this spirochete were used to test human sera to determine which antigens were diagnostically important. In analyses for immunoglobulin M (IgM) antibodies, 14 (82%) of 17 serum samples from persons who had erythema migrans reacted positively by an ELISA with one or more recombinant antigens. There was frequent antibody reactivity to protein 41-G (p41-G), outer surface protein C (OspC), and OspF antigens. In an ELISA for IgG antibodies, 13 (87%) of 15 serum samples had antibodies to recombinant antigens; reactivity to p22, p39, p41-G, OspC, and OspF antigens was frequent. By both ELISAs, serum specimens positive for OspB, OspE, and p37 were uncommon. Analyses of sera obtained from persons who were suspected of having human granulocytic ehrlichiosis (HGE) but who lacked antibodies to ehrlichiae revealed IgM antibodies to all recombinant antigens of B. burgdorferi except OspB and IgG antibodies to all antigens except OspE. Immunoblotting of sera from the study group of individuals suspected of having HGE reaffirmed antibody reactivity to multiple antigens of B. burgdorferi. There was minor cross-reactivity when sera from healthy subjects or persons who had syphilis, oral infections, or rheumatoid arthritis were tested by ELISAs with p37, p41-G, OspB, OspC, OspE, and OspF antigens. Although the results of class-specific ELISAs with recombinant antigens were comparable to those recorded for assays with whole-cell antigen and for individuals with confirmed clinical diagnoses of Lyme borreliosis, immunoblotting is still advised as an adjunct procedure, particularly when there are low antibody titers by an ELISA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10790090      PMCID: PMC86574     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Characterization of the heat shock response and identification of heat shock protein antigens of Borrelia burgdorferi.

Authors:  M M Carreiro; D C Laux; D R Nelson
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

2.  Intrathecal production of specific antibodies against Borrelia burgdorferi in patients with lymphocytic meningoradiculitis (Bannwarth's syndrome).

Authors:  B Wilske; G Schierz; V Preac-Mursic; K von Busch; R Kühbeck; H W Pfister; K Einhäupl
Journal:  J Infect Dis       Date:  1986-02       Impact factor: 5.226

3.  Measurement of antibodies to the Borrelia burgdorferi flagellum improves serodiagnosis in Lyme disease.

Authors:  K Hansen; P Hindersson; N S Pedersen
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

4.  Enzyme-linked immunosorbent assays for the detection of class-specific immunoglobulins to Borrelia burgdorferi.

Authors:  L A Magnarelli; J F Anderson
Journal:  Am J Epidemiol       Date:  1988-04       Impact factor: 4.897

5.  Cross-reactivity of nonspecific treponemal antibody in serologic tests for Lyme disease.

Authors:  L A Magnarelli; J N Miller; J F Anderson; G R Riviere
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

6.  Reactivity of human Lyme borreliosis sera with a 39-kilodalton antigen specific to Borrelia burgdorferi.

Authors:  W J Simpson; M E Schrumpf; T G Schwan
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

7.  Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE.

Authors:  F T Liang; A C Steere; A R Marques; B J Johnson; J N Miller; M T Philipp
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

8.  The Borrelia burgdorferi 37-kilodalton immunoblot band (P37) used in serodiagnosis of early lyme disease is the flaA gene product.

Authors:  R D Gilmore; R L Murphree; A M James; S A Sullivan; B J Johnson
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

9.  Serodiagnosis of Lyme borreliosis by western immunoblot: reactivity of various significant antibodies against Borrelia burgdorferi.

Authors:  B Ma; B Christen; D Leung; C Vigo-Pelfrey
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

10.  The 93-kilodalton protein of Borrelia burgdorferi: an immunodominant protoplasmic cylinder antigen.

Authors:  B J Luft; S Mudri; W Jiang; R J Dattwyler; P D Gorevic; T Fischer; P Munoz; J J Dunn; W H Schubach
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

View more
  33 in total

1.  Identification of Borrelia burgdorferi ribosomal protein L25 by the phage surface display method and evaluation of the protein's value for serodiagnosis.

Authors:  Markus Mueller; Sebastian Bunk; Isabel Diterich; Michael Weichel; Carolin Rauter; Dieter Hassler; Corinna Hermann; Reto Crameri; Thomas Hartung
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

2.  Leptospira immunoglobulin-like proteins as a serodiagnostic marker for acute leptospirosis.

Authors:  Julio Croda; João G R Ramos; James Matsunaga; Adriano Queiroz; Akira Homma; Lee W Riley; David A Haake; Mitermayer G Reis; Albert I Ko
Journal:  J Clin Microbiol       Date:  2007-03-14       Impact factor: 5.948

3.  Evaluation of the recombinant VlsE-based liaison chemiluminescence immunoassay for detection of Borrelia burgdorferi and diagnosis of Lyme disease.

Authors:  Thomas B Ledue; Marilyn F Collins; John Young; Martin E Schriefer
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

4.  Development of an enzyme-linked immunosorbent assay using a recombinant LigA fragment comprising repeat domains 4 to 7.5 as an antigen for diagnosis of equine leptospirosis.

Authors:  Weiwei Yan; Muhammad Hassan Saleem; Patrick McDonough; Sean P McDonough; Thomas J Divers; Yung-Fu Chang
Journal:  Clin Vaccine Immunol       Date:  2013-05-29

5.  OspE-related, OspF-related, and Elp lipoproteins are immunogenic in baboons experimentally infected with Borrelia burgdorferi and in human lyme disease patients.

Authors:  P Scott Hefty; Chad S Brooks; Amy M Jett; Gary L White; Stephen K Wikel; Ronald C Kennedy; Darrin R Akins
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

6.  Humoral immune response associated with lyme borreliosis in nonhuman primates: analysis by immunoblotting and enzyme-linked immunosorbent assay with sonicates or recombinant proteins.

Authors:  A R Pachner; D Dail; L Li; L Gurey; S Feng; E Hodzic; S Barthold
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

7.  Species-specific serodiagnosis of Lyme arthritis and neuroborreliosis due to Borrelia burgdorferi sensu stricto, B. afzelii, and B. garinii by using decorin binding protein A.

Authors:  Tero Heikkilä; Ilkka Seppälä; Harri Saxen; Jaana Panelius; Heta Yrjänäinen; Pekka Lahdenne
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

8.  BBK07, a dominant in vivo antigen of Borrelia burgdorferi, is a potential marker for serodiagnosis of Lyme disease.

Authors:  Adam S Coleman; Utpal Pal
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

9.  Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease.

Authors:  Gary P Wormser; Martin Schriefer; Maria E Aguero-Rosenfeld; Andrew Levin; Allen C Steere; Robert B Nadelman; John Nowakowski; Adriana Marques; Barbara J B Johnson; J Stephen Dumler
Journal:  Diagn Microbiol Infect Dis       Date:  2012-10-11       Impact factor: 2.803

10.  Novel Diagnosis of Lyme Disease: Potential for CAM Intervention.

Authors:  Aristo Vojdani; Frank Hebroni; Yaniv Raphael; Jonathan Erde; Bernard Raxlen
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-15       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.